Bill Text: NY A00110 | 2019-2020 | General Assembly | Introduced

---

Bill Title: Requires homeless shelters to keep an opioid antagonist on hand, have at least one trained employee on duty at all times, sets out the requirements for the training of those employees, and develops a training plan for opioid overdoses in conjunction with a registered opioid overdose prevention program.

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Introduced - Dead) 2020-01-08 - referred to codes [A00110 Detail]

Download: New_York-2019-A00110-Introduced.html

---

                STATE OF NEW YORK
        ________________________________________________________________________
                                           110
                               2019-2020 Regular Sessions
                   IN ASSEMBLY
                                       (Prefiled)
                                     January 9, 2019
                                       ___________
        Introduced  by  M.  of  A. L. ROSENTHAL -- read once and referred to the
          Committee on Social Services
        AN ACT to amend the social services law, in relation to requiring  home-
          less  shelters to keep an opioid antagonist on hand, have at least one
          trained employee on duty at all times, and provide  an  opioid  antag-
          onist training program for residents
          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:
     1    Section 1. Article 2-A of the social services law is amended by adding
     2  a new title 3 to read as follows:
     3                                   TITLE 3
     4                   OPIOID ANTAGONISTS IN HOMELESS SHELTERS
     5  Section 47. Opioid antagonist use and training.
     6    § 47. Opioid antagonist use and training. 1. Any provider of temporary
     7  housing assistance, which shall include, but not be limited to, a family
     8  shelter, a shelter for adults, a hotel, an emergency apartment, a domes-
     9  tic violence shelter, a runaway and homeless youth shelter,  or  a  safe
    10  house for refugees operating in this state shall have at its premises at
    11  all times:
    12    (a)  an  opioid  antagonist  and  a method of administering it on site
    13  which may include, but not be limited to, a naloxone kit; and
    14    (b) at a minimum, one employee trained in  the  administration  of  an
    15  opioid antagonist on duty at all times.
    16    2.  All  employees of providers of temporary public housing assistance
    17  who are authorized to administer an opioid antagonist shall:
    18    (a) have completed an initial training program, which  may  include  a
    19  department  of  health  registered  opioid  overdose prevention training
    20  program;
    21    (b) complete a refresher training program at least every two years;
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD01857-01-9
        A. 110                              2
     1    (c) contact the emergency medical system  during  any  response  to  a
     2  victim  of suspected drug overdose and advise if an opioid antagonist is
     3  being used;
     4    (d)  comply  with  protocols for response to victims of suspected drug
     5  overdose; and
     6    (e) report all responses to victims of suspected drug overdose to  the
     7  department of health.
     8    3.  All  providers  of  temporary  housing  assistance shall develop a
     9  training  plan  in  conjunction  with  a  registered   opioid   overdose
    10  prevention program in the applicable region regarding the administration
    11  of  opioid  antagonists to any individual residing on a provider's prem-
    12  ises who is at risk of experiencing or witnessing an opioid overdose.
    13    4. For the purposes of this subdivision, the term "opioid  antagonist"
    14  shall  mean  a  federal food and drug administration-approved drug that,
    15  when administered, negates or neutralizes in whole or in part the  phar-
    16  macological  effects  of  an  opioid  in the body and that is limited to
    17  naloxone or other medications approved by the department of  health  for
    18  this  purpose and "naloxone kit" shall mean a prefilled naloxone syringe
    19  or needle-free intranasal drug delivery device.
    20    5. The commissioner is authorized to promulgate rules and  regulations
    21  necessary for the implementation of this title.
    22    §  2.  This  act shall take effect on the thirtieth day after it shall
    23  have become a law. Effective immediately, the addition, amendment and/or
    24  repeal of any rule or regulation necessary  for  the  implementation  of
    25  this  act  on its effective date are authorized to be made and completed
    26  on or before such effective date.